MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum
MiMedx Group, a leader in advanced wound care, announced its upcoming presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiMedx Group, a leader in advanced wound care, announced its upcoming presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. CEO Timothy R. Wright and CFO Peter M. Carlson will represent the company. A live webcast will be available on the company’s website. This forum highlights MiMedx's commitment to innovation in therapeutic biologics, specifically in human placental tissue allografts, which have exceeded two million shipments to date.
Details
News Market Reaction – MDXG
The recorded move for MDXG in the trading session of this news was +6.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link below.
Date: Thursday, November 19, 2020
Time: 9:30 AM ET
Webcast: https://wsw.com/webcast/canaccord44/mdxg/2454624
A replay of the webcast will be available for approximately 45 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.
About MiMedx
MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact
Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
investorrelations@mimedx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.